Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with chemotherapy in triple-negative breast cancer
NCT04770272Phase 2Terminated
- Sponsor
- Palleos Healthcare
- Start
- Mar 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Palleos Healthcare. Started Mar 2021; status: terminated.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04770272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770272.